Melanoma is the deadliest form of skin cancer.
We aim to understand mechanisms underlying disease progression in order to better predict and identify aggressive forms of melanomas. The serine/threonine kinase, BRAF, is somatically mutated in 40-60% of melanomas. BRAF mutations are early events that lead to hyper-activation of MEK-ERK1/2 signaling and melanoma growth and invasion. While BRAF inhibitors are now first-line therapies for metastasized mutant V600E BRAF melanomas, they only delay mortality and are not being administered in the adjuvant setting. Thus, we must enhance our understanding of the mechanisms underlying growth and invasion of early-stage melanomas in order to improve early diagnosis and treatment strategies that prevent metastasis. We have identified transcription factors, TWIST1 and FOXD3, which are regulated by mutant BRAF in melanoma. In this proposal, we seek to determine the role of TWIST1 and FOXD3 in invasion and dormancy during the early steps of melanoma progression. We propose three Specific Aims to determine the role of TWIST1 in invasion of primary melanoma using 3D skin mimetic and mutant BRAF mouse models, to mechanistically understand FOXD3 regulation of SOX2 (a transcription factor linked to induced pluripotency), and to examine the interplay between TWIST1, FOXD3 and SOX2 in vivo. At the completion of our experiments, we expect to have demonstrated that the interplay between mutant BRAF-regulated transcription factors controls mechanisms that underlie melanoma plasticity and steps in the metastatic cascade.

Public Health Relevance

Melanoma is an aggressive cancer type and the mechanisms underlying distinct steps in the metastatic cascade remain unclear. This application addresses how a common driver mutation regulates transcription factors to control the progression of early-stage melanoma. We expect that our results will lead to an enhanced understanding of progression and metastasis in this deadly cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA196278-03
Application #
9264500
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2015-06-24
Project End
2020-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
3
Fiscal Year
2017
Total Cost
$356,850
Indirect Cost
$128,100
Name
Thomas Jefferson University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693
Hartsough, Edward J; Kugel 3rd, Curtis H; Vido, Michael J et al. (2018) Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo. Mol Cancer Ther 17:84-95
Teh, Jessica L F; Aplin, Andrew E (2018) Playing the Melanoma Endgame. Clin Cancer Res 24:4629-4630
Vu, Ha Linh; Aplin, Andrew E (2016) Targeting mutant NRAS signaling pathways in melanoma. Pharmacol Res 107:111-116
Hartsough, Edward J; Aplin, Andrew E (2016) Of Mice and Melanoma: PDX System for Modeling Personalized Medicine. Clin Cancer Res 22:1550-2